AI주식인사이트AI Stock Insight
C

강스템바이오텍

217730KOSDAQ기초 의약물질 제조업

53.0 / 100

Reference Date: 2026-04-13

Financial Score13.5 / 40
News Sentiment12.5 / 25
Momentum17.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but PBR raises overvaluation concerns. Surged 39.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Kansstem Biotech, established in 2010, specializes in developing and manufacturing stem cell therapies, with core businesses in stem cell treatments and cosmetics. The stem cell division focuses on therapies for conditions like atopic dermatitis and rheumatoid arthritis, while the cosmetics division sells stem cell-derived products through online channels. The company also develops new drugs based on exosome technology for wound healing and hair loss.

Number of Employees

172people

Average Salary

57.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 33.454.0Point
PBR
4.90Industry Average 2.030.0Point

2.4x industry avg (risky)

ROE
-18.65Industry Average -4.293.5Point

4.3x industry avg (excellent)

Debt Ratio
5.98Industry Average 6.614.0Point

In line with industry avg

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼46.5% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲7.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -29.2% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 0Neutral 0Negative 1Average Sentiment Score 50

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 3,600Won52-week high 3,60052-week low 1,171
1-month return6.0Point

1m +39.53% (strong rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-04-03
  • Neutral주식매수선택권부여에관한신고2026-03-31
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
  • Neutral정기주주총회결과2026-03-30
  • Neutral사업보고서 (2025.12)2026-03-20